Division of Nuclear Medicine, Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA.
Clin Nucl Med. 2018 Jul;43(7):e226-e231. doi: 10.1097/RLU.0000000000002130.
F-fluciclovine is a synthetic amino acid radiotracer that has recently been approved in Europe and the United States for PET imaging in men with biochemical recurrence (BCR) of prostate cancer after prior definitive treatment. Accurate identification of the sites of disease in patients presenting with BCR of prostate cancer is important in determining the appropriate treatment. Bone is the most frequent site of metastatic disease in patients with prostate cancer.
We conducted a comprehensive review of the available preclinical and clinical data on the diagnostic performance of F-fluciclovine PET/CT in an attempt to draw practical and general conclusions on the utility and limitations of F-fluciclovine PET/CT in localization of osseous metastatic disease in prostate cancer.
The cumulative preclinical data and results of some retrospective and 2 prospective clinical studies suggest that F-fluciclovine can detect early bone marrow involvement in patients with BCR of prostate cancer and negative prior bone-specific imaging findings.
F-fluciclovine PET/CT seems to offer useful information for early detection of bone metastases in men with BCR of prostate cancer. Additional investigations will be needed to compare the diagnostic performance of F-fluciclovine PET/CT to other standard and novel imaging methods in initial staging, BCR, and castrate-resistant phases of disease.
F-氟代赖氨酸是一种合成氨基酸示踪剂，最近在欧洲和美国获得批准，可用于先前根治性治疗后前列腺癌生化复发（BCR）男性的 PET 成像。准确识别 BCR 前列腺癌患者的疾病部位对于确定适当的治疗方法很重要。骨骼是前列腺癌患者转移性疾病最常见的部位。
我们对 F-氟代赖氨酸 PET/CT 在诊断前列腺癌骨转移中的应用的现有临床前和临床数据进行了全面回顾，试图对 F-氟代赖氨酸 PET/CT 的实用性和局限性得出实用和一般的结论。
累积的临床前数据和一些回顾性和 2 项前瞻性临床研究的结果表明，F-氟代赖氨酸可检测到 BCR 前列腺癌患者和先前阴性骨特异性成像发现的骨髓早期受累。
F-氟代赖氨酸 PET/CT 似乎为 BCR 前列腺癌男性骨转移的早期检测提供了有用的信息。需要进一步研究来比较 F-氟代赖氨酸 PET/CT 与其他标准和新型成像方法在初始分期、BCR 和去势抵抗期疾病中的诊断性能。
